SAN DIEGO

,

Sept. 1, 2021

/PRNewswire/ — Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that Chief Executive Officer

Saundra Pelletier

will present and host one-on-one meetings at two upcoming investor conferences as follows:

Webcasts of both events will be available through the Events section of the Evofem website at

https://evofem.investorroom.com/events

for 30 days.

About Evofem Biosciences


Evofem Biosciences, Inc., (NASDAQ: EVFM) is developing and commercializing innovative products to address unmet needs in women’s sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). The Company launched its first FDA-approved commercial product,

Phexxi

^®

(lactic acid, citric acid and potassium bitartrate), in the United States in September 2020. The Company is evaluating lead product candidate EVO100 for the prevention of urogenital

Chlamydia trachomatis

and

Neisseria gonorrhoeae

infection in women in the ongoing Phase 3 clinical trial,

‘EVOGUARD

.’ For more information, please visit

evofem.com

.

Phexxi

^®

is a registered trademark of Evofem Biosciences, Inc.

Investor Relations Contact



Amy Raskopf


Evofem Biosciences, Inc.



[email protected]



Mobile: (917) 673-5775

View original content to download multimedia:

https://www.prnewswire.com/news-releases/evofem-biosciences-to-participate-in-investor-conferences-301367047.html

SOURCE Evofem Biosciences, Inc.